Literature DB >> 16644016

B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.

Marinos C Dalakas1.   

Abstract

There is evidence that B cells are involved in the pathophysiology of many neurological diseases, either in a causative or contributory role, via production of autoantibodies, cytokine secretion, or by acting as antigen-presenting cells leading to T cell activation. Clonal expansion of B cells either in situ or intrathecally and circulating autoantibodies are critical elements in multiple sclerosis (MS), Devic's disease, paraneoplastic central nervous system disorders, stiff-person syndrome, myasthenia gravis, autoimmune demyelinating neuropathies and dermatomyositis. The pathogenic role of B cells and autoantibodies in central and peripheral nervous system disorders, as reviewed here, provides a rationale for investigating whether depletion of B cells with new agents can improve clinical symptomatology and, potentially, restore immune function. Preliminary results from several clinical studies and case reports suggest that B cell depletion may become a viable alternative approach to the treatment of autoimmune neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644016     DOI: 10.1016/j.pharmthera.2006.03.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  13 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 2.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

3.  CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.

Authors:  P M Abraham; S H Quan; D Dukala; B Soliven
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

4.  Successful treatment of paraneoplastic cerebellar degeneration with Rituximab.

Authors:  Marcello Esposito; P Penza; G Orefice; A Pagano; E Parente; A Abbadessa; V Bonavita
Journal:  J Neurooncol       Date:  2007-10-09       Impact factor: 4.130

5.  Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.

Authors:  Brandon A Brown; Mina Torabi
Journal:  Drug Saf       Date:  2011-02-01       Impact factor: 5.606

Review 6.  [Targeting B cells in multiple sclerosis. Current concepts and strategies].

Authors:  T Menge; H-C Büdingen; M C Dalakas; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

7.  B cells as a target of immune modulation.

Authors:  Kathleen Hawker
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  Frequent involvement of central nervous system in primary Sjögren syndrome.

Authors:  Isabel Moreira; Filipa Teixeira; Ana Martins Silva; Carlos Vasconcelos; Fátima Farinha; Ernestina Santos
Journal:  Rheumatol Int       Date:  2014-07-24       Impact factor: 2.631

Review 9.  Research advancement in immunopathogenesis of myasthenia gravis.

Authors:  Sha Huang; Li-Ming Tan
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

Review 10.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.